Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00781274 | Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy | PHASE3 | COMPLETED | 32 | — | — | Dec 1, 2008 | Jul 1, 2010 | Jan 6, 2026 | 1 | Japan |
| NCT00780416 | Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C | PHASE3 | COMPLETED | 189 | — | — | Nov 1, 2008 | Aug 1, 2010 | Jan 6, 2026 | 1 | Japan |
| NCT00621296 | Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C | PHASE2 | COMPLETED | 15 | — | — | Jan 1, 2008 | Feb 1, 2009 | Jan 6, 2026 | 1 | Japan |
| NCT00630058 | A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C | PHASE1 | COMPLETED | 20 | — | — | Apr 1, 2008 | Mar 1, 2009 | Jan 6, 2026 | 1 | Japan |
Data were collected before the first dose in the morning, and at 1, 2.5, 4, 6, 8, 12, 16 and 24 h after the first dose on days 1, 14 and 85. Data as pre-dose were collected at Day3, Day8, Day29, Day43 and Day57.
Data were collected before the first dose in the morning, and at 1, 2.5, 4, 6, 8, 12, 16 and 24 h after the first dose on days 1, 14 and 85. Data as pre-dose were collected at Day3, Day8, Day29, Day43 and Day57.
Data were collected before the first dose in the morning, and at 1, 2.5, 4, 6, 8, 12, 16 and 24 h after the first dose on days 1, 14 and 85. Data as pre-dose were collected at Day3, Day8, Day29, Day43 and Day57.
Data were collected before the first dose in the morning, and at 1, 2.5, 4, 6, 8, 12, 16 and 24 h after the first dose on days 1, 14 and 85. Data as pre-dose were collected at Day3, Day8, Day29, Day43 and Day57.
Data were collected before the first dose in the morning, and at 1, 2.5, 4, 6, 8, 12, 16 and 24 h after the first dose on days 1, 14 and 85. Data as pre-dose were collected at Day3, Day8, Day29, Day43 and Day57.
| Arm | Type | Description |
|---|---|---|
| MP-424 | EXPERIMENTAL | - |
| TRV/PEG/RBV | EXPERIMENTAL | - |
| PEG/RBV | ACTIVE_COMPARATOR | - |
| Group A (MP-424 High) | EXPERIMENTAL | - |
| Group B (MP-424 Low) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MP-424 | DRUG | 750 mg every 8 hours for 12 weeks |
| Ribavirin | DRUG | 600 - 1000 mg/day based on body weight for 24 weeks |
| Peginterferon Alfa-2b | DRUG | 1.5 mcg/kg/week for 24 weeks |
| MP-424 (Telaprevir) | DRUG | Three tablets of MP-424 250mg tablet at a time, every 8 hours, 24 weeks administration (dose in a day: 2250 mg) |
| MP-424(H), PEG-IFN-a-2b, RBV | DRUG | MP-424 (three tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks |
| MP-424 (L), PEG-IFN-a-2b, RBV | DRUG | MP-424 (two tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks |
Inclusion Criteria: * Genotype 1, chronic hepatitis C * Non-responders (patient who did not respond to previous treatment) * Able and willing to follow contraception requirements Exclusion Criteria: * Cirrhosis of the liver or hepatic failure * Hepatitis B surface antigen-positive or HIV antibodi...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | — | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | — | Undisclosed |